Advertisement
Screener

Kailera Therapeutics, Inc. (KLRA) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Kailera Therapeutics, Inc. Operating Cash Flow

Kailera Therapeutics, Inc. (KLRA) reported Operating Cash Flow of -$145.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12

  • Kailera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$77.53M.
  • Kailera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$68.31M.
  • Kailera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$26.23M.
  • Kailera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$18.20M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 month
2026-06-30-$77.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$145.84M
10-Q · filed 2026-08-12
2026-03-31-$68.31M
10-Q · filed 2026-05-26
2025-06-30-$26.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$44.43M
10-Q · filed 2026-08-12
2025-03-31-$18.20M
10-Q · filed 2026-05-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74